IRB #

STUDY00016085

Title

[NCI CIRB] A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Principal Investigator

Christopher Ryan

Study Purpose

The purpose of this study is to compare the effects of three drugs, crizotinib, cabozantinib and savolitinib, to see if any of them slow tumor growth in advanced kidney cancer better then the standard treatment, sunitinib.

Medical Condition(s)

Kidney cancer

Eligibility Criteria

18 years or older with confirmed advanced kidney cancer. Further tests, procedures, and exams will be done to further confirm eligibility.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

For as long as the participant is seeing benefit from the study drug

Minors Included

No

Contact

Knight Clinical Trials
trials@ohsu.edu

Sponsor

SWOG

Recruitment End

07/30/2018

Compensation Provided

No


Go Back